New Therapies to Correct the Cystic Fibrosis Basic Defect
Rare diseases affect 400 million individuals worldwide and cause significant morbidity and mortality. Finding solutions for rare diseases can be very challenging for physicians and researchers. Cystic fibrosis (CF), a genetic, autosomal recessive, multisystemic, life-limiting disease does not escape...
Main Authors: | Christelle Bergeron, André M. Cantin |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-06-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/12/6193 |
Similar Items
-
Emerging Therapeutic Approaches for Cystic Fibrosis. From Gene Editing to Personalized Medicine
by: Iwona Pranke, et al.
Published: (2019-02-01) -
Profile of tezacaftor/ivacaftor combination and its potential in the treatment of cystic fibrosis
by: Shiferaw D, et al.
Published: (2019-08-01) -
Activity of lumacaftor is not conserved in zebrafish Cftr bearing the major cystic fibrosis‐causing mutation
by: Onofrio Laselva, et al.
Published: (2019-10-01) -
Demographic characteristics, clinical and laboratory features, and the distribution of pathogenic variants in the CFTR gene in the Cypriot cystic fibrosis (CF) population demonstrate the utility of a national CF patient registry
by: Panayiotis K. Yiallouros, et al.
Published: (2021-10-01) -
Taking stock of gene therapy for cystic fibrosis
by: Alton Eric WFW, et al.
Published: (2000-09-01)